MEF2A and Miyoshi myopathy: miR-144, downregulated in MM patients and MM cell lines, targets MEF2a (myocyte enhancer factor 2A) and inhibits the proliferation, migration and angiogenesis of MM cells and the overexpression reverses the effects [132].